Trials / Active Not Recruiting
Active Not RecruitingNCT04870047
Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Phenox GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device | Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device. |
Timeline
- Start date
- 2021-09-03
- Primary completion
- 2024-12-04
- Completion
- 2025-12-01
- First posted
- 2021-05-03
- Last updated
- 2025-06-04
Locations
18 sites across 7 countries: France, Germany, Israel, Italy, Slovakia, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT04870047. Inclusion in this directory is not an endorsement.